US EditionImpact of RSVpreF Vaccination on Reducing the Burden of Respiratory Syncytial Virus in Infants and Older Adults
6 Articles
6 Articles
Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults
Respiratory syncytial virus (RSV) causes a substantial health burden among infants and older adults. Prefusion F protein-based vaccines have shown high efficacy against RSV disease in clinical trials, offering promise for mitigating this burden through maternal and older adult immunization. Employing an individual-based model, we evaluated the impact of RSV vaccination on hospitalizations and deaths in 13 high-income countries, assuming that the…
Vaccination against the Respiratory Syncicial Virus (RSV) in pregnant women is essential to reduce severe cases in newborns, especially in the current context of low temperatures, where respiratory diseases increase.The Ministry of Health of Entre Ríos recalls the importance of this immunization, aimed at pregnant women between 32 and 36 weeks and six days of gestation.VSR is one of the main causes of low acute respiratory infections in infants …
Turning Insight into Action at the RSV Expert Meeting - Immunisation Coalition
The RSV Expert Meeting brought together over 100 in-person attendees and more than 300 online participants to explore the evolving landscape of respiratory syncytial virus prevention and immunisation in Australia. The meeting featured leading experts discussing RSV infection trends among infants and older adults, early outcomes from the monoclonal antibody program, and insights from the maternal vaccination rollout. Strategies to improve vaccina…
News Moderna International Stock Exchanges Receives FDA Approval for VRS Vaccine (mRESVIA) in Adults
Market Consensus CdM Moderna has announced that the U.S. Medicines Administration (FDA) has approved mRESVIA (mRNA-1345), mRNA vaccine for the prevention of lower respiratory tract disease caused by the syncytial respiratory virus (SVR), in people 18 to 59 years of age at higher risk of contracting the disease. This approval extends the previous indication of the FDA and the European Medicines Agency (EMA) for mRESVIA, [...]
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
